Bafna Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 10, 2025, 8:14 pm

Competitors of Bafna Pharmaceuticals Ltd

All Competitor Stocks of Bafna Pharmaceuticals Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:15 pm

Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 34.62 Cr.. The value appears to be declining and may need further review. It has decreased from 39.06 Cr. (Mar 2025) to 34.62 Cr., marking a decrease of 4.44 Cr..
• For Expenses, as of Jun 2025, the value is 29.55 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.95 Cr. (Mar 2025) to 29.55 Cr., marking a decrease of 6.40 Cr..
• For Operating Profit, as of Jun 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 3.11 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 1.96 Cr..
• For OPM %, as of Jun 2025, the value is 14.64%. The value appears strong and on an upward trend. It has increased from 7.96% (Mar 2025) to 14.64%, marking an increase of 6.68%.
• For Other Income, as of Jun 2025, the value is 0.60 Cr.. The value appears strong and on an upward trend. It has increased from -0.76 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 1.36 Cr..
• For Interest, as of Jun 2025, the value is 0.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Mar 2025) to 0.91 Cr., marking an increase of 0.09 Cr..
• For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.22 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 1.15 Cr..
• For Profit before tax, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
• For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
• For Net Profit, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.43. The value appears strong and on an upward trend. It has increased from 0.55 (Mar 2025) to 1.43, marking an increase of 0.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 22, 2025, 5:26 pm

Growth

Last Updated: September 5, 2025, 12:15 am

Balance Sheet

Last Updated: September 10, 2025, 1:31 pm

Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
• For Reserves, as of Mar 2025, the value is 61.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to 61.00 Cr., marking an increase of 4.00 Cr..
• For Borrowings, as of Mar 2025, the value is 28.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 24.00 Cr. (Mar 2024) to 28.00 Cr., marking an increase of 4.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 40.00 Cr.. The value appears to be improving (decreasing). It has decreased from 42.00 Cr. (Mar 2024) to 40.00 Cr., marking a decrease of 2.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 153.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Mar 2024) to 153.00 Cr., marking an increase of 5.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 59.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to 59.00 Cr., marking an increase of 19.00 Cr..
• For CWIP, as of Mar 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2024) to 7.00 Cr., marking a decrease of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 95.00 Cr. (Mar 2024) to 87.00 Cr., marking a decrease of 8.00 Cr..
• For Total Assets, as of Mar 2025, the value is 153.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2024) to 153.00 Cr., marking an increase of 5.00 Cr..

Notably, the Reserves (61.00 Cr.) exceed the Borrowings (28.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
• For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
• For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
• For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
• For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
• For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
• For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
• For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
• For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
• For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
• For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
• For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
• For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
• For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
• For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
• For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
• For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
• For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
• For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
• For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
• For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
• For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
• For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
• For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
• For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
• For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
• For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
• For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
• For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
• For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness